SIGA (SIGA)

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Its lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic National Stockpile under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a contract with Biomedical Advanced Research and Development Authority (BARDA) for additional procurement and development related to both oral and intravenous formulations of TPOXX.

Company profile

Ticker

SIGA

Exchange

NASDAQ

Website

www.siga.com

CEO

Phillip Louis Gomez

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

SIGA PHARMACEUTICALS INC

SEC CIK

0001010086

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

133864870

SIGA stock data

1M 1Y 5Y

News

From Benzinga Pro

SIGA Technologies Announces $13M Worth Order For Its Monkeypox Treatment

23 Jun 22

'Germany reports 71 new monkeypox cases, the biggest one-day increase on record' -BNN Report

23 Jun 22

https://twitter.com/BNNBreaking/status/1539947728112959489

SIGA Announces $13M Of International Procurement Orders For Oral TPOXX (Tecovirimat)

23 Jun 22

SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of procurement orders for oral TPOXX

'25 people have tested positive for orthopoxvirus in NYC, which is presumed to be monkeypox' -NYC Healthy Tweet

21 Jun 22

'Germany reports 57 new monkeypox cases as daily cases continue to rise' - Tweet By BNN Newsroom

21 Jun 22

Press releases

From Benzinga Pro

Thinking about buying stock in Revlon, CNS Pharmaceuticals, SIGA Technologies, Freeport-McMoRan, or Kirkland's?

23 Jun 22

NEW YORK, June 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for REV, CNSP, SIGA, FCX, and KIRK.

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

23 Jun 22

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $13 million of

SIGA to Participate in Alliance Global Partners' Monkeypox Panel on Thursday, June 23rd 2022

22 Jun 22

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its Chief Executive

Thinking about buying stock in Concert Pharmaceuticals, PMV Pharmaceuticals, Allbirds, SIGA Technologies, or Elevation Oncology?

27 May 22

Global Psychedelics Market Is Expected To Reach $8 Billion By 2029

24 May 22

Calendar

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart SIGA financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	153.26M	153.26M	153.26M	153.26M	153.26M	153.26M
Cash burn (monthly)	(no burn)	(no burn)	479.63K	(no burn)	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	1.38M	n/a	n/a	n/a
Cash remaining	n/a	n/a	151.88M	n/a	n/a	n/a
Runway (months of cash)	n/a	n/a	316.7	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from SIGA earnings reports.

Recent insider trades

SIGA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Jun 22	Antal James	Common Stock, par value $.0001 per share	Sale back to company	Dispose D	No	No	10.26	6,849	70.27K	116,857
14 Jun 22	Antal James	Common Stock, par value $.0001 per share	Option exercise	Acquire M	No	No	0	22,831	0	123,706
14 Jun 22	Antal James	RSU Common Stock, par value $.0001 per share	Grant	Acquire A	No	No	0	14,620	0	14,620
14 Jun 22	Antal James	RSU Common Stock, par value $.0001 per share	Option exercise	Dispose M	No	No	0	22,831	0	0
14 Jun 22	Jaymie A Durnan	Common Stock, par value $.0001 per share	Sale back to company	Dispose D	No	No	10.26	6,849	70.27K	30,982
14 Jun 22	Jaymie A Durnan	Common Stock, par value $.0001 per share	Option exercise	Acquire M	No	No	0	22,831	0	37,831
14 Jun 22	Jaymie A Durnan	RSU Common Stock, par value $.0001 per share	Grant	Acquire A	No	No	0	14,620	0	14,620
14 Jun 22	Jaymie A Durnan	RSU Common Stock, par value $.0001 per share	Option exercise	Dispose M	No	No	0	22,831	0	0
14 Jun 22	Kane Julie	Common Stock, par value $.0001 per share	Sale back to company	Dispose D	No	No	10.26	6,849	70.27K	48,482
14 Jun 22	Kane Julie	Common Stock, par value $.0001 per share	Option exercise	Acquire M	No	No	0	22,831	0	55,331

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

SIGA institutional ownership history Ownership history

32.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	109	120	-9.2%
Opened positions	8	21	-61.9%
Closed positions	19	9	+111.1%
Increased positions	28	34	-17.6%
Reduced positions	45	41	+9.8%

13F shares	Current	Prev Q	Change
Total value	172.93M	429.36M	-59.7%
Total shares	23.59M	24.55M	-3.9%
Total puts	24K	47.7K	-49.7%
Total calls	139.7K	512.5K	-72.7%
Total put/call ratio	0.2	0.1	+84.6%

Largest owners	Shares	Value	Change
BLK Blackrock	3.59M	$25.44M	-3.7%
AltraVue Capital	2.47M	$17.53M	-1.1%
Esopus Creek Value Series Fund LP - Series A	2.37M	$21.94M	0.0%
Vanguard	2.23M	$15.84M	-0.0%
Kempen Capital Management	1.38M	$9.76M	+19.5%
Price Michael F	1.15M	$8.14M	0.0%
STT State Street	1.06M	$7.55M	+1.6%
Dimensional Fund Advisors	952.63K	$6.76M	+4.9%
Geode Capital Management	813.99K	$5.77M	+0.9%
Renaissance Technologies	685.31K	$4.86M	-23.3%

Largest transactions	Shares	Bought/sold	Change
Kempen Capital Management	1.38M	+224.42K	+19.5%
Renaissance Technologies	685.31K	-208.19K	-23.3%
Allspring Global Investments	272.14K	-195.63K	-41.8%
WFC Wells Fargo & Co.	93.43K	-173.73K	-65.0%
GS Goldman Sachs	126.12K	-165.88K	-56.8%
Arrowstreet Capital, Limited Partnership	69.76K	-163.37K	-70.1%
Hillsdale Investment Management	159.91K	+159.91K	NEW
BLK Blackrock	3.59M	-137.47K	-3.7%
Russell Investments	173.17K	-126.18K	-42.2%
Citadel Advisors	122.33K	+99.23K	+429.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.